nodes	percent_of_prediction	percent_of_DWPC	metapath
Epirubicin—UGT2B7—Mycophenolic acid—systemic scleroderma	0.323	0.582	CbGbCtD
Epirubicin—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.18	0.325	CbGbCtD
Epirubicin—ABCC1—Methotrexate—systemic scleroderma	0.0514	0.0927	CbGbCtD
Epirubicin—AURKA—Integrin-linked kinase signaling—GIT2—systemic scleroderma	0.00493	0.183	CbGpPWpGaD
Epirubicin—CHD1—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.00482	0.536	CbGdCrCtD
Epirubicin—CHD1—tendon—systemic scleroderma	0.00298	0.0713	CbGeAlD
Epirubicin—Doxorubicin—NOS3—systemic scleroderma	0.00294	1	CrCbGaD
Epirubicin—AURKA—Aurora A signaling—CENPA—systemic scleroderma	0.00272	0.101	CbGpPWpGaD
Epirubicin—YWHAG—connective tissue—systemic scleroderma	0.00269	0.0642	CbGeAlD
Epirubicin—DHCR7—skin of body—systemic scleroderma	0.00264	0.0632	CbGeAlD
Epirubicin—CHD1—lung—systemic scleroderma	0.00262	0.0626	CbGeAlD
Epirubicin—AURKA—digestive system—systemic scleroderma	0.00253	0.0604	CbGeAlD
Epirubicin—YWHAG—smooth muscle tissue—systemic scleroderma	0.00246	0.0587	CbGeAlD
Epirubicin—AURKA—tendon—systemic scleroderma	0.00241	0.0575	CbGeAlD
Epirubicin—AURKA—Aurora B signaling—CENPA—systemic scleroderma	0.00217	0.0809	CbGpPWpGaD
Epirubicin—DHCR7—digestive system—systemic scleroderma	0.00211	0.0505	CbGeAlD
Epirubicin—AURKA—lung—systemic scleroderma	0.00211	0.0505	CbGeAlD
Epirubicin—PLA2G4A—connective tissue—systemic scleroderma	0.002	0.0479	CbGeAlD
Epirubicin—YWHAG—digestive system—systemic scleroderma	0.00194	0.0464	CbGeAlD
Epirubicin—YWHAG—tendon—systemic scleroderma	0.00185	0.0441	CbGeAlD
Epirubicin—PLA2G4A—smooth muscle tissue—systemic scleroderma	0.00183	0.0438	CbGeAlD
Epirubicin—DHCR7—lung—systemic scleroderma	0.00177	0.0422	CbGeAlD
Epirubicin—UGT2B7—digestive system—systemic scleroderma	0.00175	0.0419	CbGeAlD
Epirubicin—YWHAG—lung—systemic scleroderma	0.00162	0.0387	CbGeAlD
Epirubicin—AURKA—Mycophenolate mofetil—Mycophenolic acid—systemic scleroderma	0.00158	0.176	CbGdCrCtD
Epirubicin—PLA2G4A—tendon—systemic scleroderma	0.00138	0.0329	CbGeAlD
Epirubicin—TOP2A—tendon—systemic scleroderma	0.00131	0.0313	CbGeAlD
Epirubicin—PLA2G4A—lung—systemic scleroderma	0.00121	0.0289	CbGeAlD
Epirubicin—TOP2A—lung—systemic scleroderma	0.00115	0.0274	CbGeAlD
Epirubicin—AURKA—Mycophenolic acid—Mycophenolate mofetil—systemic scleroderma	0.000895	0.0997	CbGdCrCtD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000876	0.0326	CbGpPWpGaD
Epirubicin—ABCC1—tendon—systemic scleroderma	0.000788	0.0188	CbGeAlD
Epirubicin—PLA2G4A—Enalapril—Captopril—systemic scleroderma	0.000777	0.0866	CbGdCrCtD
Epirubicin—ABCC1—lung—systemic scleroderma	0.000691	0.0165	CbGeAlD
Epirubicin—YWHAG—a6b1 and a6b4 Integrin signaling—IL1A—systemic scleroderma	0.000686	0.0256	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—COL1A2—systemic scleroderma	0.00059	0.022	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000583	0.0217	CbGpPWpGaD
Epirubicin—PLA2G4A—Prostaglandin Synthesis and Regulation—EDN1—systemic scleroderma	0.000579	0.0215	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.000544	0.0202	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000483	0.018	CbGpPWpGaD
Epirubicin—YWHAG—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000473	0.0176	CbGpPWpGaD
Epirubicin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—IL1A—systemic scleroderma	0.000464	0.0173	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CENPC—systemic scleroderma	0.000432	0.0161	CbGpPWpGaD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000432	0.0161	CbGpPWpGaD
Epirubicin—PLA2G4A—Raltitrexed—Methotrexate—systemic scleroderma	0.00043	0.0479	CbGdCrCtD
Epirubicin—TOP2A—Circadian rythm related genes—TOP1—systemic scleroderma	0.000414	0.0154	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL13—systemic scleroderma	0.000404	0.015	CbGpPWpGaD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000374	0.0139	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000366	0.0136	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—CSK—systemic scleroderma	0.00033	0.0123	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CENPC—systemic scleroderma	0.000328	0.0122	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—EDN1—systemic scleroderma	0.00032	0.0119	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.000307	0.0114	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.0003	0.0112	CbGpPWpGaD
Epirubicin—AURKA—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000291	0.0108	CbGpPWpGaD
Epirubicin—PLA2G4A—PDGFR-beta signaling pathway—BLK—systemic scleroderma	0.000287	0.0107	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—systemic scleroderma	0.000283	0.0105	CbGpPWpGaD
Epirubicin—AURKA—Cell Cycle—CENPA—systemic scleroderma	0.000275	0.0102	CbGpPWpGaD
Epirubicin—PLA2G4A—Endothelins—MMP1—systemic scleroderma	0.000269	0.01	CbGpPWpGaD
Epirubicin—PLA2G4A—Enalapril—Lisinopril—systemic scleroderma	0.000256	0.0286	CbGdCrCtD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CENPC—systemic scleroderma	0.000256	0.00954	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL1A—systemic scleroderma	0.000254	0.00945	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—SELP—systemic scleroderma	0.000246	0.00914	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.000233	0.00866	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—RHOB—systemic scleroderma	0.000229	0.00854	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CENPC—systemic scleroderma	0.000229	0.00853	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	0.000227	0.00846	CbGpPWpGaD
Epirubicin—YWHAG—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—systemic scleroderma	0.000213	0.00793	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—CSK—systemic scleroderma	0.000209	0.00778	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—CENPA—systemic scleroderma	0.000208	0.00775	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP2—systemic scleroderma	0.0002	0.00745	CbGpPWpGaD
Epirubicin—AURKA—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000199	0.00742	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—NOS3—systemic scleroderma	0.000188	0.00698	CbGpPWpGaD
Epirubicin—PLA2G4A—Platelet homeostasis—NOS3—systemic scleroderma	0.000164	0.00611	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle, Mitotic—CENPA—systemic scleroderma	0.000163	0.00606	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—NOS3—systemic scleroderma	0.000156	0.00582	CbGpPWpGaD
Epirubicin—PLA2G4A—AGE/RAGE pathway—MMP9—systemic scleroderma	0.000151	0.0056	CbGpPWpGaD
Epirubicin—TOP2A—Cell Cycle—CENPA—systemic scleroderma	0.000146	0.00542	CbGpPWpGaD
Epirubicin—YWHAG—Cell Cycle—TGFB1—systemic scleroderma	0.000145	0.00538	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—HSPG2—systemic scleroderma	0.000134	0.00497	CbGpPWpGaD
Epirubicin—YWHAG—Myometrial Relaxation and Contraction Pathways—IL1B—systemic scleroderma	0.000133	0.00495	CbGpPWpGaD
Epirubicin—YWHAG—SIDS Susceptibility Pathways—IL1B—systemic scleroderma	0.000132	0.00493	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—SELP—systemic scleroderma	0.000127	0.00471	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—RHOB—systemic scleroderma	0.000118	0.0044	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—CSK—systemic scleroderma	0.000108	0.00401	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	0.000101	0.00378	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—ITGAM—systemic scleroderma	0.000101	0.00377	CbGpPWpGaD
Epirubicin—DHCR7—Metabolism—CTGF—systemic scleroderma	0.000101	0.00377	CbGpPWpGaD
Epirubicin—Anxiety—Mycophenolate mofetil—systemic scleroderma	9.5e-05	0.00026	CcSEcCtD
Epirubicin—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	9.49e-05	0.00026	CcSEcCtD
Epirubicin—Hypersensitivity—Azathioprine—systemic scleroderma	9.47e-05	0.00026	CcSEcCtD
Epirubicin—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	9.47e-05	0.00026	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	9.47e-05	0.00026	CcSEcCtD
Epirubicin—Insomnia—Lisinopril—systemic scleroderma	9.44e-05	0.000259	CcSEcCtD
Epirubicin—Discomfort—Mycophenolate mofetil—systemic scleroderma	9.42e-05	0.000258	CcSEcCtD
Epirubicin—Paraesthesia—Lisinopril—systemic scleroderma	9.37e-05	0.000257	CcSEcCtD
Epirubicin—Vomiting—Captopril—systemic scleroderma	9.37e-05	0.000257	CcSEcCtD
Epirubicin—Dry mouth—Mycophenolate mofetil—systemic scleroderma	9.33e-05	0.000256	CcSEcCtD
Epirubicin—Dyspnoea—Lisinopril—systemic scleroderma	9.3e-05	0.000255	CcSEcCtD
Epirubicin—Rash—Captopril—systemic scleroderma	9.29e-05	0.000255	CcSEcCtD
Epirubicin—Dermatitis—Captopril—systemic scleroderma	9.28e-05	0.000254	CcSEcCtD
Epirubicin—Somnolence—Lisinopril—systemic scleroderma	9.28e-05	0.000254	CcSEcCtD
Epirubicin—Headache—Captopril—systemic scleroderma	9.23e-05	0.000253	CcSEcCtD
Epirubicin—Confusional state—Mycophenolate mofetil—systemic scleroderma	9.22e-05	0.000253	CcSEcCtD
Epirubicin—Dyspepsia—Lisinopril—systemic scleroderma	9.18e-05	0.000252	CcSEcCtD
Epirubicin—Body temperature increased—Mycophenolic acid—systemic scleroderma	9.16e-05	0.000251	CcSEcCtD
Epirubicin—Abdominal pain—Mycophenolic acid—systemic scleroderma	9.16e-05	0.000251	CcSEcCtD
Epirubicin—Oedema—Mycophenolate mofetil—systemic scleroderma	9.14e-05	0.000251	CcSEcCtD
Epirubicin—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	9.14e-05	0.000251	CcSEcCtD
Epirubicin—Asthma—Methotrexate—systemic scleroderma	9.11e-05	0.00025	CcSEcCtD
Epirubicin—Infection—Mycophenolate mofetil—systemic scleroderma	9.08e-05	0.000249	CcSEcCtD
Epirubicin—Decreased appetite—Lisinopril—systemic scleroderma	9.07e-05	0.000249	CcSEcCtD
Epirubicin—Eosinophilia—Methotrexate—systemic scleroderma	9.02e-05	0.000247	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Lisinopril—systemic scleroderma	9.01e-05	0.000247	CcSEcCtD
Epirubicin—Fatigue—Lisinopril—systemic scleroderma	9e-05	0.000247	CcSEcCtD
Epirubicin—Shock—Mycophenolate mofetil—systemic scleroderma	8.99e-05	0.000246	CcSEcCtD
Epirubicin—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	8.97e-05	0.000246	CcSEcCtD
Epirubicin—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	8.95e-05	0.000245	CcSEcCtD
Epirubicin—Hypersensitivity—Leflunomide—systemic scleroderma	8.95e-05	0.000245	CcSEcCtD
Epirubicin—Pancreatitis—Methotrexate—systemic scleroderma	8.93e-05	0.000245	CcSEcCtD
Epirubicin—Pain—Lisinopril—systemic scleroderma	8.92e-05	0.000245	CcSEcCtD
Epirubicin—Constipation—Lisinopril—systemic scleroderma	8.92e-05	0.000245	CcSEcCtD
Epirubicin—Tachycardia—Mycophenolate mofetil—systemic scleroderma	8.92e-05	0.000245	CcSEcCtD
Epirubicin—Skin disorder—Mycophenolate mofetil—systemic scleroderma	8.88e-05	0.000243	CcSEcCtD
Epirubicin—Bradycardia—Prednisone—systemic scleroderma	8.88e-05	0.000243	CcSEcCtD
Epirubicin—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	8.84e-05	0.000242	CcSEcCtD
Epirubicin—Diarrhoea—Azathioprine—systemic scleroderma	8.8e-05	0.000241	CcSEcCtD
Epirubicin—Haemoglobin—Prednisone—systemic scleroderma	8.77e-05	0.00024	CcSEcCtD
Epirubicin—Nausea—Captopril—systemic scleroderma	8.75e-05	0.00024	CcSEcCtD
Epirubicin—Haemorrhage—Prednisone—systemic scleroderma	8.72e-05	0.000239	CcSEcCtD
Epirubicin—Anorexia—Mycophenolate mofetil—systemic scleroderma	8.71e-05	0.000239	CcSEcCtD
Epirubicin—Asthenia—Leflunomide—systemic scleroderma	8.71e-05	0.000239	CcSEcCtD
Epirubicin—Pancytopenia—Methotrexate—systemic scleroderma	8.65e-05	0.000237	CcSEcCtD
Epirubicin—Feeling abnormal—Lisinopril—systemic scleroderma	8.6e-05	0.000236	CcSEcCtD
Epirubicin—Pruritus—Leflunomide—systemic scleroderma	8.59e-05	0.000235	CcSEcCtD
Epirubicin—Connective tissue disorder—Prednisone—systemic scleroderma	8.57e-05	0.000235	CcSEcCtD
Epirubicin—Hypotension—Mycophenolate mofetil—systemic scleroderma	8.54e-05	0.000234	CcSEcCtD
Epirubicin—Gastrointestinal pain—Lisinopril—systemic scleroderma	8.53e-05	0.000234	CcSEcCtD
Epirubicin—Neutropenia—Methotrexate—systemic scleroderma	8.52e-05	0.000233	CcSEcCtD
Epirubicin—Dysuria—Methotrexate—systemic scleroderma	8.52e-05	0.000233	CcSEcCtD
Epirubicin—Dizziness—Azathioprine—systemic scleroderma	8.5e-05	0.000233	CcSEcCtD
Epirubicin—Upper respiratory tract infection—Methotrexate—systemic scleroderma	8.46e-05	0.000232	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	8.33e-05	0.000228	CcSEcCtD
Epirubicin—Photosensitivity reaction—Methotrexate—systemic scleroderma	8.31e-05	0.000228	CcSEcCtD
Epirubicin—Asthenia—Mycophenolic acid—systemic scleroderma	8.31e-05	0.000228	CcSEcCtD
Epirubicin—Diarrhoea—Leflunomide—systemic scleroderma	8.31e-05	0.000228	CcSEcCtD
Epirubicin—Urticaria—Lisinopril—systemic scleroderma	8.29e-05	0.000227	CcSEcCtD
Epirubicin—Insomnia—Mycophenolate mofetil—systemic scleroderma	8.27e-05	0.000227	CcSEcCtD
Epirubicin—Abdominal pain—Lisinopril—systemic scleroderma	8.25e-05	0.000226	CcSEcCtD
Epirubicin—Body temperature increased—Lisinopril—systemic scleroderma	8.25e-05	0.000226	CcSEcCtD
Epirubicin—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	8.21e-05	0.000225	CcSEcCtD
Epirubicin—Pruritus—Mycophenolic acid—systemic scleroderma	8.2e-05	0.000225	CcSEcCtD
Epirubicin—Vomiting—Azathioprine—systemic scleroderma	8.18e-05	0.000224	CcSEcCtD
Epirubicin—Pneumonia—Methotrexate—systemic scleroderma	8.17e-05	0.000224	CcSEcCtD
Epirubicin—Eye disorder—Prednisone—systemic scleroderma	8.15e-05	0.000223	CcSEcCtD
Epirubicin—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	8.15e-05	0.000223	CcSEcCtD
Epirubicin—Somnolence—Mycophenolate mofetil—systemic scleroderma	8.13e-05	0.000223	CcSEcCtD
Epirubicin—Infestation NOS—Methotrexate—systemic scleroderma	8.12e-05	0.000223	CcSEcCtD
Epirubicin—Drowsiness—Methotrexate—systemic scleroderma	8.12e-05	0.000223	CcSEcCtD
Epirubicin—Infestation—Methotrexate—systemic scleroderma	8.12e-05	0.000223	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	8.11e-05	0.00302	CbGpPWpGaD
Epirubicin—Rash—Azathioprine—systemic scleroderma	8.11e-05	0.000222	CcSEcCtD
Epirubicin—Dermatitis—Azathioprine—systemic scleroderma	8.1e-05	0.000222	CcSEcCtD
Epirubicin—Flushing—Prednisone—systemic scleroderma	8.09e-05	0.000222	CcSEcCtD
Epirubicin—Headache—Azathioprine—systemic scleroderma	8.06e-05	0.000221	CcSEcCtD
Epirubicin—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	8.05e-05	0.000221	CcSEcCtD
Epirubicin—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	8.05e-05	0.000221	CcSEcCtD
Epirubicin—Dizziness—Leflunomide—systemic scleroderma	8.03e-05	0.00022	CcSEcCtD
Epirubicin—Renal failure—Methotrexate—systemic scleroderma	7.98e-05	0.000219	CcSEcCtD
Epirubicin—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	7.95e-05	0.000218	CcSEcCtD
Epirubicin—Diarrhoea—Mycophenolic acid—systemic scleroderma	7.93e-05	0.000217	CcSEcCtD
Epirubicin—Stomatitis—Methotrexate—systemic scleroderma	7.92e-05	0.000217	CcSEcCtD
Epirubicin—Angiopathy—Prednisone—systemic scleroderma	7.91e-05	0.000217	CcSEcCtD
Epirubicin—Conjunctivitis—Methotrexate—systemic scleroderma	7.89e-05	0.000216	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	7.89e-05	0.000216	CcSEcCtD
Epirubicin—Immune system disorder—Prednisone—systemic scleroderma	7.88e-05	0.000216	CcSEcCtD
Epirubicin—Constipation—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000214	CcSEcCtD
Epirubicin—Pain—Mycophenolate mofetil—systemic scleroderma	7.82e-05	0.000214	CcSEcCtD
Epirubicin—Arrhythmia—Prednisone—systemic scleroderma	7.79e-05	0.000214	CcSEcCtD
Epirubicin—Sweating—Methotrexate—systemic scleroderma	7.78e-05	0.000213	CcSEcCtD
Epirubicin—Haematuria—Methotrexate—systemic scleroderma	7.74e-05	0.000212	CcSEcCtD
Epirubicin—Vomiting—Leflunomide—systemic scleroderma	7.72e-05	0.000212	CcSEcCtD
Epirubicin—Alopecia—Prednisone—systemic scleroderma	7.71e-05	0.000211	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	7.69e-05	0.00286	CbGpPWpGaD
Epirubicin—Hypersensitivity—Lisinopril—systemic scleroderma	7.69e-05	0.000211	CcSEcCtD
Epirubicin—Hepatobiliary disease—Methotrexate—systemic scleroderma	7.68e-05	0.00021	CcSEcCtD
Epirubicin—Dizziness—Mycophenolic acid—systemic scleroderma	7.66e-05	0.00021	CcSEcCtD
Epirubicin—Epistaxis—Methotrexate—systemic scleroderma	7.66e-05	0.00021	CcSEcCtD
Epirubicin—Rash—Leflunomide—systemic scleroderma	7.66e-05	0.00021	CcSEcCtD
Epirubicin—Dermatitis—Leflunomide—systemic scleroderma	7.65e-05	0.00021	CcSEcCtD
Epirubicin—Mental disorder—Prednisone—systemic scleroderma	7.64e-05	0.000209	CcSEcCtD
Epirubicin—Nausea—Azathioprine—systemic scleroderma	7.64e-05	0.000209	CcSEcCtD
Epirubicin—Headache—Leflunomide—systemic scleroderma	7.61e-05	0.000208	CcSEcCtD
Epirubicin—Erythema—Prednisone—systemic scleroderma	7.59e-05	0.000208	CcSEcCtD
Epirubicin—Malnutrition—Prednisone—systemic scleroderma	7.59e-05	0.000208	CcSEcCtD
Epirubicin—Agranulocytosis—Methotrexate—systemic scleroderma	7.58e-05	0.000208	CcSEcCtD
Epirubicin—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	7.53e-05	0.000206	CcSEcCtD
Epirubicin—Asthenia—Lisinopril—systemic scleroderma	7.49e-05	0.000205	CcSEcCtD
Epirubicin—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	7.48e-05	0.000205	CcSEcCtD
Epirubicin—Pruritus—Lisinopril—systemic scleroderma	7.38e-05	0.000202	CcSEcCtD
Epirubicin—Vomiting—Mycophenolic acid—systemic scleroderma	7.37e-05	0.000202	CcSEcCtD
Epirubicin—Haemoglobin—Methotrexate—systemic scleroderma	7.33e-05	0.000201	CcSEcCtD
Epirubicin—Rash—Mycophenolic acid—systemic scleroderma	7.3e-05	0.0002	CcSEcCtD
Epirubicin—Dermatitis—Mycophenolic acid—systemic scleroderma	7.3e-05	0.0002	CcSEcCtD
Epirubicin—Hepatitis—Methotrexate—systemic scleroderma	7.29e-05	0.0002	CcSEcCtD
Epirubicin—Haemorrhage—Methotrexate—systemic scleroderma	7.29e-05	0.0002	CcSEcCtD
Epirubicin—Urticaria—Mycophenolate mofetil—systemic scleroderma	7.26e-05	0.000199	CcSEcCtD
Epirubicin—Headache—Mycophenolic acid—systemic scleroderma	7.26e-05	0.000199	CcSEcCtD
Epirubicin—Pharyngitis—Methotrexate—systemic scleroderma	7.23e-05	0.000198	CcSEcCtD
Epirubicin—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000198	CcSEcCtD
Epirubicin—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	7.23e-05	0.000198	CcSEcCtD
Epirubicin—Nausea—Leflunomide—systemic scleroderma	7.21e-05	0.000198	CcSEcCtD
Epirubicin—Urinary tract disorder—Methotrexate—systemic scleroderma	7.2e-05	0.000197	CcSEcCtD
Epirubicin—Vision blurred—Prednisone—systemic scleroderma	7.16e-05	0.000196	CcSEcCtD
Epirubicin—Urethral disorder—Methotrexate—systemic scleroderma	7.15e-05	0.000196	CcSEcCtD
Epirubicin—Diarrhoea—Lisinopril—systemic scleroderma	7.14e-05	0.000196	CcSEcCtD
Epirubicin—Ill-defined disorder—Prednisone—systemic scleroderma	7.04e-05	0.000193	CcSEcCtD
Epirubicin—Visual impairment—Methotrexate—systemic scleroderma	7.02e-05	0.000193	CcSEcCtD
Epirubicin—Anaemia—Prednisone—systemic scleroderma	7.02e-05	0.000192	CcSEcCtD
Epirubicin—Agitation—Prednisone—systemic scleroderma	6.98e-05	0.000191	CcSEcCtD
Epirubicin—Dizziness—Lisinopril—systemic scleroderma	6.9e-05	0.000189	CcSEcCtD
Epirubicin—Erythema multiforme—Methotrexate—systemic scleroderma	6.89e-05	0.000189	CcSEcCtD
Epirubicin—Nausea—Mycophenolic acid—systemic scleroderma	6.88e-05	0.000189	CcSEcCtD
Epirubicin—Malaise—Prednisone—systemic scleroderma	6.85e-05	0.000188	CcSEcCtD
Epirubicin—Vertigo—Prednisone—systemic scleroderma	6.82e-05	0.000187	CcSEcCtD
Epirubicin—Eye disorder—Methotrexate—systemic scleroderma	6.81e-05	0.000187	CcSEcCtD
Epirubicin—Syncope—Prednisone—systemic scleroderma	6.81e-05	0.000187	CcSEcCtD
Epirubicin—Tinnitus—Methotrexate—systemic scleroderma	6.8e-05	0.000186	CcSEcCtD
Epirubicin—PLA2G4A—Signaling by GPCR—RHOB—systemic scleroderma	6.78e-05	0.00253	CbGpPWpGaD
Epirubicin—Cardiac disorder—Methotrexate—systemic scleroderma	6.77e-05	0.000185	CcSEcCtD
Epirubicin—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	6.74e-05	0.000185	CcSEcCtD
Epirubicin—UGT2B7—NRF2 pathway—TGFB1—systemic scleroderma	6.7e-05	0.0025	CbGpPWpGaD
Epirubicin—Loss of consciousness—Prednisone—systemic scleroderma	6.67e-05	0.000183	CcSEcCtD
Epirubicin—Vomiting—Lisinopril—systemic scleroderma	6.63e-05	0.000182	CcSEcCtD
Epirubicin—Angiopathy—Methotrexate—systemic scleroderma	6.61e-05	0.000181	CcSEcCtD
Epirubicin—Immune system disorder—Methotrexate—systemic scleroderma	6.58e-05	0.00018	CcSEcCtD
Epirubicin—Rash—Lisinopril—systemic scleroderma	6.58e-05	0.00018	CcSEcCtD
Epirubicin—Convulsion—Prednisone—systemic scleroderma	6.58e-05	0.00018	CcSEcCtD
Epirubicin—Dermatitis—Lisinopril—systemic scleroderma	6.57e-05	0.00018	CcSEcCtD
Epirubicin—Mediastinal disorder—Methotrexate—systemic scleroderma	6.57e-05	0.00018	CcSEcCtD
Epirubicin—Asthenia—Mycophenolate mofetil—systemic scleroderma	6.56e-05	0.00018	CcSEcCtD
Epirubicin—Hypertension—Prednisone—systemic scleroderma	6.56e-05	0.00018	CcSEcCtD
Epirubicin—Chills—Methotrexate—systemic scleroderma	6.54e-05	0.000179	CcSEcCtD
Epirubicin—Headache—Lisinopril—systemic scleroderma	6.54e-05	0.000179	CcSEcCtD
Epirubicin—Pruritus—Mycophenolate mofetil—systemic scleroderma	6.47e-05	0.000177	CcSEcCtD
Epirubicin—Myalgia—Prednisone—systemic scleroderma	6.46e-05	0.000177	CcSEcCtD
Epirubicin—Arthralgia—Prednisone—systemic scleroderma	6.46e-05	0.000177	CcSEcCtD
Epirubicin—Anxiety—Prednisone—systemic scleroderma	6.44e-05	0.000177	CcSEcCtD
Epirubicin—Alopecia—Methotrexate—systemic scleroderma	6.44e-05	0.000177	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	6.42e-05	0.000176	CcSEcCtD
Epirubicin—Discomfort—Prednisone—systemic scleroderma	6.39e-05	0.000175	CcSEcCtD
Epirubicin—Mental disorder—Methotrexate—systemic scleroderma	6.39e-05	0.000175	CcSEcCtD
Epirubicin—Erythema—Methotrexate—systemic scleroderma	6.35e-05	0.000174	CcSEcCtD
Epirubicin—Malnutrition—Methotrexate—systemic scleroderma	6.35e-05	0.000174	CcSEcCtD
Epirubicin—PLA2G4A—Betamethasone—Mometasone—systemic scleroderma	6.29e-05	0.00701	CbGdCrCtD
Epirubicin—PLA2G4A—Dexamethasone—Mometasone—systemic scleroderma	6.29e-05	0.00701	CbGdCrCtD
Epirubicin—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	6.25e-05	0.000171	CcSEcCtD
Epirubicin—Dysgeusia—Methotrexate—systemic scleroderma	6.21e-05	0.00017	CcSEcCtD
Epirubicin—Nausea—Lisinopril—systemic scleroderma	6.2e-05	0.00017	CcSEcCtD
Epirubicin—Oedema—Prednisone—systemic scleroderma	6.2e-05	0.00017	CcSEcCtD
Epirubicin—Anaphylactic shock—Prednisone—systemic scleroderma	6.2e-05	0.00017	CcSEcCtD
Epirubicin—Infection—Prednisone—systemic scleroderma	6.16e-05	0.000169	CcSEcCtD
Epirubicin—ABCC1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	6.15e-05	0.00229	CbGpPWpGaD
Epirubicin—Back pain—Methotrexate—systemic scleroderma	6.14e-05	0.000168	CcSEcCtD
Epirubicin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	6.12e-05	0.00228	CbGpPWpGaD
Epirubicin—Shock—Prednisone—systemic scleroderma	6.1e-05	0.000167	CcSEcCtD
Epirubicin—Nervous system disorder—Prednisone—systemic scleroderma	6.08e-05	0.000167	CcSEcCtD
Epirubicin—Tachycardia—Prednisone—systemic scleroderma	6.05e-05	0.000166	CcSEcCtD
Epirubicin—Dizziness—Mycophenolate mofetil—systemic scleroderma	6.05e-05	0.000166	CcSEcCtD
Epirubicin—Skin disorder—Prednisone—systemic scleroderma	6.02e-05	0.000165	CcSEcCtD
Epirubicin—Hyperhidrosis—Prednisone—systemic scleroderma	5.99e-05	0.000164	CcSEcCtD
Epirubicin—Vision blurred—Methotrexate—systemic scleroderma	5.98e-05	0.000164	CcSEcCtD
Epirubicin—ABCC1—Disease—SMAD7—systemic scleroderma	5.91e-05	0.0022	CbGpPWpGaD
Epirubicin—Anorexia—Prednisone—systemic scleroderma	5.91e-05	0.000162	CcSEcCtD
Epirubicin—Ill-defined disorder—Methotrexate—systemic scleroderma	5.89e-05	0.000161	CcSEcCtD
Epirubicin—Anaemia—Methotrexate—systemic scleroderma	5.87e-05	0.000161	CcSEcCtD
Epirubicin—Vomiting—Mycophenolate mofetil—systemic scleroderma	5.81e-05	0.000159	CcSEcCtD
Epirubicin—Rash—Mycophenolate mofetil—systemic scleroderma	5.76e-05	0.000158	CcSEcCtD
Epirubicin—Dermatitis—Mycophenolate mofetil—systemic scleroderma	5.76e-05	0.000158	CcSEcCtD
Epirubicin—Headache—Mycophenolate mofetil—systemic scleroderma	5.73e-05	0.000157	CcSEcCtD
Epirubicin—Malaise—Methotrexate—systemic scleroderma	5.72e-05	0.000157	CcSEcCtD
Epirubicin—Vertigo—Methotrexate—systemic scleroderma	5.7e-05	0.000156	CcSEcCtD
Epirubicin—Leukopenia—Methotrexate—systemic scleroderma	5.68e-05	0.000156	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Prednisone—systemic scleroderma	5.65e-05	0.000155	CcSEcCtD
Epirubicin—Insomnia—Prednisone—systemic scleroderma	5.6e-05	0.000154	CcSEcCtD
Epirubicin—Paraesthesia—Prednisone—systemic scleroderma	5.56e-05	0.000152	CcSEcCtD
Epirubicin—Cough—Methotrexate—systemic scleroderma	5.54e-05	0.000152	CcSEcCtD
Epirubicin—Convulsion—Methotrexate—systemic scleroderma	5.5e-05	0.000151	CcSEcCtD
Epirubicin—Dyspepsia—Prednisone—systemic scleroderma	5.45e-05	0.000149	CcSEcCtD
Epirubicin—Nausea—Mycophenolate mofetil—systemic scleroderma	5.43e-05	0.000149	CcSEcCtD
Epirubicin—ABCC1—Disease—TGFBI—systemic scleroderma	5.41e-05	0.00201	CbGpPWpGaD
Epirubicin—Arthralgia—Methotrexate—systemic scleroderma	5.4e-05	0.000148	CcSEcCtD
Epirubicin—Chest pain—Methotrexate—systemic scleroderma	5.4e-05	0.000148	CcSEcCtD
Epirubicin—Myalgia—Methotrexate—systemic scleroderma	5.4e-05	0.000148	CcSEcCtD
Epirubicin—Decreased appetite—Prednisone—systemic scleroderma	5.39e-05	0.000148	CcSEcCtD
Epirubicin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	5.37e-05	0.000147	CcSEcCtD
Epirubicin—Fatigue—Prednisone—systemic scleroderma	5.34e-05	0.000146	CcSEcCtD
Epirubicin—Discomfort—Methotrexate—systemic scleroderma	5.34e-05	0.000146	CcSEcCtD
Epirubicin—PLA2G4A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	5.3e-05	0.00197	CbGpPWpGaD
Epirubicin—Constipation—Prednisone—systemic scleroderma	5.3e-05	0.000145	CcSEcCtD
Epirubicin—Confusional state—Methotrexate—systemic scleroderma	5.22e-05	0.000143	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—SMAD7—systemic scleroderma	5.18e-05	0.00193	CbGpPWpGaD
Epirubicin—Anaphylactic shock—Methotrexate—systemic scleroderma	5.18e-05	0.000142	CcSEcCtD
Epirubicin—Infection—Methotrexate—systemic scleroderma	5.15e-05	0.000141	CcSEcCtD
Epirubicin—Feeling abnormal—Prednisone—systemic scleroderma	5.11e-05	0.00014	CcSEcCtD
Epirubicin—Nervous system disorder—Methotrexate—systemic scleroderma	5.08e-05	0.000139	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—MMP1—systemic scleroderma	5.07e-05	0.00189	CbGpPWpGaD
Epirubicin—Thrombocytopenia—Methotrexate—systemic scleroderma	5.07e-05	0.000139	CcSEcCtD
Epirubicin—Gastrointestinal pain—Prednisone—systemic scleroderma	5.07e-05	0.000139	CcSEcCtD
Epirubicin—Skin disorder—Methotrexate—systemic scleroderma	5.03e-05	0.000138	CcSEcCtD
Epirubicin—Hyperhidrosis—Methotrexate—systemic scleroderma	5.01e-05	0.000137	CcSEcCtD
Epirubicin—Anorexia—Methotrexate—systemic scleroderma	4.94e-05	0.000135	CcSEcCtD
Epirubicin—Urticaria—Prednisone—systemic scleroderma	4.92e-05	0.000135	CcSEcCtD
Epirubicin—Abdominal pain—Prednisone—systemic scleroderma	4.9e-05	0.000134	CcSEcCtD
Epirubicin—Body temperature increased—Prednisone—systemic scleroderma	4.9e-05	0.000134	CcSEcCtD
Epirubicin—Hypotension—Methotrexate—systemic scleroderma	4.84e-05	0.000133	CcSEcCtD
Epirubicin—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	4.72e-05	0.000129	CcSEcCtD
Epirubicin—PLA2G4A—Platelet activation, signaling and aggregation—TGFB1—systemic scleroderma	4.72e-05	0.00176	CbGpPWpGaD
Epirubicin—Insomnia—Methotrexate—systemic scleroderma	4.68e-05	0.000128	CcSEcCtD
Epirubicin—Paraesthesia—Methotrexate—systemic scleroderma	4.65e-05	0.000127	CcSEcCtD
Epirubicin—Dyspnoea—Methotrexate—systemic scleroderma	4.62e-05	0.000127	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—HSPG2—systemic scleroderma	4.61e-05	0.00172	CbGpPWpGaD
Epirubicin—Somnolence—Methotrexate—systemic scleroderma	4.6e-05	0.000126	CcSEcCtD
Epirubicin—Hypersensitivity—Prednisone—systemic scleroderma	4.57e-05	0.000125	CcSEcCtD
Epirubicin—Dyspepsia—Methotrexate—systemic scleroderma	4.56e-05	0.000125	CcSEcCtD
Epirubicin—PLA2G4A—Metabolism—HSPG2—systemic scleroderma	4.52e-05	0.00168	CbGpPWpGaD
Epirubicin—Decreased appetite—Methotrexate—systemic scleroderma	4.5e-05	0.000123	CcSEcCtD
Epirubicin—Gastrointestinal disorder—Methotrexate—systemic scleroderma	4.47e-05	0.000123	CcSEcCtD
Epirubicin—Fatigue—Methotrexate—systemic scleroderma	4.47e-05	0.000122	CcSEcCtD
Epirubicin—Asthenia—Prednisone—systemic scleroderma	4.45e-05	0.000122	CcSEcCtD
Epirubicin—Pain—Methotrexate—systemic scleroderma	4.43e-05	0.000121	CcSEcCtD
Epirubicin—DHCR7—Metabolism—NOS3—systemic scleroderma	4.4e-05	0.00164	CbGpPWpGaD
Epirubicin—Pruritus—Prednisone—systemic scleroderma	4.38e-05	0.00012	CcSEcCtD
Epirubicin—ABCC1—Disease—HSPG2—systemic scleroderma	4.31e-05	0.00161	CbGpPWpGaD
Epirubicin—Feeling abnormal—Methotrexate—systemic scleroderma	4.27e-05	0.000117	CcSEcCtD
Epirubicin—Diarrhoea—Prednisone—systemic scleroderma	4.24e-05	0.000116	CcSEcCtD
Epirubicin—Gastrointestinal pain—Methotrexate—systemic scleroderma	4.23e-05	0.000116	CcSEcCtD
Epirubicin—ABCC1—Disease—CSK—systemic scleroderma	4.16e-05	0.00155	CbGpPWpGaD
Epirubicin—Urticaria—Methotrexate—systemic scleroderma	4.11e-05	0.000113	CcSEcCtD
Epirubicin—Dizziness—Prednisone—systemic scleroderma	4.1e-05	0.000112	CcSEcCtD
Epirubicin—Body temperature increased—Methotrexate—systemic scleroderma	4.09e-05	0.000112	CcSEcCtD
Epirubicin—Abdominal pain—Methotrexate—systemic scleroderma	4.09e-05	0.000112	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—RHOB—systemic scleroderma	4.01e-05	0.00149	CbGpPWpGaD
Epirubicin—Vomiting—Prednisone—systemic scleroderma	3.94e-05	0.000108	CcSEcCtD
Epirubicin—ABCC1—Disease—CD247—systemic scleroderma	3.92e-05	0.00146	CbGpPWpGaD
Epirubicin—Rash—Prednisone—systemic scleroderma	3.91e-05	0.000107	CcSEcCtD
Epirubicin—Dermatitis—Prednisone—systemic scleroderma	3.9e-05	0.000107	CcSEcCtD
Epirubicin—Headache—Prednisone—systemic scleroderma	3.88e-05	0.000106	CcSEcCtD
Epirubicin—Hypersensitivity—Methotrexate—systemic scleroderma	3.82e-05	0.000105	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—HSPG2—systemic scleroderma	3.78e-05	0.00141	CbGpPWpGaD
Epirubicin—Asthenia—Methotrexate—systemic scleroderma	3.72e-05	0.000102	CcSEcCtD
Epirubicin—Nausea—Prednisone—systemic scleroderma	3.68e-05	0.000101	CcSEcCtD
Epirubicin—PLA2G4A—Hemostasis—NOS3—systemic scleroderma	3.68e-05	0.00137	CbGpPWpGaD
Epirubicin—Pruritus—Methotrexate—systemic scleroderma	3.66e-05	0.0001	CcSEcCtD
Epirubicin—PLA2G4A—Signaling Pathways—CSK—systemic scleroderma	3.65e-05	0.00136	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—HSPG2—systemic scleroderma	3.61e-05	0.00134	CbGpPWpGaD
Epirubicin—Diarrhoea—Methotrexate—systemic scleroderma	3.54e-05	9.71e-05	CcSEcCtD
Epirubicin—UGT2B7—Metabolism—CTGF—systemic scleroderma	3.49e-05	0.0013	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—EDN1—systemic scleroderma	3.46e-05	0.00129	CbGpPWpGaD
Epirubicin—PLA2G4A—Dexamethasone—Prednisone—systemic scleroderma	3.43e-05	0.00382	CbGdCrCtD
Epirubicin—PLA2G4A—Betamethasone—Prednisone—systemic scleroderma	3.43e-05	0.00382	CbGdCrCtD
Epirubicin—PLA2G4A—Metabolism—CTGF—systemic scleroderma	3.43e-05	0.00128	CbGpPWpGaD
Epirubicin—Dizziness—Methotrexate—systemic scleroderma	3.42e-05	9.38e-05	CcSEcCtD
Epirubicin—Vomiting—Methotrexate—systemic scleroderma	3.29e-05	9.02e-05	CcSEcCtD
Epirubicin—Rash—Methotrexate—systemic scleroderma	3.27e-05	8.95e-05	CcSEcCtD
Epirubicin—Dermatitis—Methotrexate—systemic scleroderma	3.26e-05	8.94e-05	CcSEcCtD
Epirubicin—Headache—Methotrexate—systemic scleroderma	3.24e-05	8.89e-05	CcSEcCtD
Epirubicin—Nausea—Methotrexate—systemic scleroderma	3.08e-05	8.43e-05	CcSEcCtD
Epirubicin—TOP2A—Methyltestosterone—Prednisone—systemic scleroderma	2.81e-05	0.00313	CbGdCrCtD
Epirubicin—ABCC1—Metabolism—CTGF—systemic scleroderma	2.74e-05	0.00102	CbGpPWpGaD
Epirubicin—PLA2G4A—Hemostasis—TGFB1—systemic scleroderma	2.43e-05	0.000905	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling by GPCR—CCL2—systemic scleroderma	2.37e-05	0.000881	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—EDN1—systemic scleroderma	2.05e-05	0.000762	CbGpPWpGaD
Epirubicin—UGT2B7—Metabolism—NOS3—systemic scleroderma	1.52e-05	0.000566	CbGpPWpGaD
Epirubicin—PLA2G4A—Metabolism—NOS3—systemic scleroderma	1.49e-05	0.000555	CbGpPWpGaD
Epirubicin—ABCC1—Disease—NOS3—systemic scleroderma	1.42e-05	0.00053	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—CCL2—systemic scleroderma	1.4e-05	0.000521	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—NOS3—systemic scleroderma	1.25e-05	0.000464	CbGpPWpGaD
Epirubicin—ABCC1—Metabolism—NOS3—systemic scleroderma	1.19e-05	0.000443	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—MMP9—systemic scleroderma	1e-05	0.000372	CbGpPWpGaD
Epirubicin—ABCC1—Disease—TGFB1—systemic scleroderma	9.41e-06	0.00035	CbGpPWpGaD
Epirubicin—PLA2G4A—Signaling Pathways—TGFB1—systemic scleroderma	8.24e-06	0.000307	CbGpPWpGaD
